After reading an interview with Dr. Elias Reichel, of Tufts University School of Medicine, concerning Allergan’s involvement with DARPin technology for use in treating wet AMD, and some further web research about the DARPin technology, I realized that an important element of Allergan’s work with DARPin is not only an improved anti-VEGF agent but a deal with Molecular Partners (the owners of the DARPin technology), announced last fall, to investigate and commercialize a dual action anti-VEGF/PDGF drug that will be both longer lasting in the eye (fewer injections needed) than current anti-VEGF drugs, but also potentially improve visual acuity in those suffering from wet AMD (and other vascular conditions), similar to the effect shown by the use of Fovista plus Lucentis that we have previously written about ^[1].

To read my full report on these developments, go to http://tinyurl.com/AMD-Update23 ^[2]